Spots Global Cancer Trial Database for Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer

Official Title: Diagnostic and Prognostic Values of EUS-FNA Specimens and Circulating Exosomal Small RNA in Patients With Pancreatic Cancer

Study ID: NCT04636788

Conditions

Pancreas Adenocarcinoma

Interventions

Venous sampling

Study Description

Brief Summary: This study is for the verification of biomarkers for pancreatic cancer treatment using small RNA liquid biopsy, combined with EUS-FNA tissues.

Detailed Description: CA19-9 is the FDA approved biomarker for the diagnosis of pancreatic cancer. However, the specificity of CA19-9 to differentiate between pancreatic cancer, cholangiocarcinoma, or other pancreatic lesions is not satisfying enough. Tumor cells secret abundant exosomes in the early stage. Circulating tumor cells are detected mainly in the advanced stage. Meanwhile, the role of non-coding RNA draws more and more attention in tumor area. Exosomes protect inside RNA from plasma RNase. Compared with long RNA, small RNA, including miRNA, snoRNA, tRNA, piRNA could exist more stably. By means of next-generation sequencing, we look forward to finding new exosomal small RNA biomarkers.